3.00 -0.02 (-0.66%)
After hours: 5:41PM EST
|Bid||2.97 x 900|
|Ask||3.05 x 27000|
|Day's Range||2.9300 - 3.1400|
|52 Week Range||1.2700 - 6.9800|
|Beta (3Y Monthly)||3.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.
Intuitive Surgical’s (ISRG) stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018, reflecting a ~34% year-to-date rise.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced its naming to Deloitte’s 2018 Technology Fast 500TM, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. “We’re thrilled to be recognized as one of Deloitte’s 2018 Technology Fast 500 companies,” said Todd M. Pope, TransEnterix president and CEO. “TransEnterix’s mission is to advance minimally invasive surgical capabilities through digital laparoscopy with the SenhanceTM Surgical System.
In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.
TransEnterix’s (TRXC) interest expense increased to $685,000 in the third quarter compared to $563,000 in the previous year’s period. TransEnterix’s net income rose from -$38.51 million in the third quarter of 2017 to -$20.21 million in the third quarter, translating to net EPS of -$0.10 in the third quarter. TransEnterix’s net EPS were -$0.26 in the third quarter of 2017.
For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.
TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.
TransEnterix (TRXC) delivered earnings and revenue surprises of 14.29% and 6.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Morrisville, North Carolina-based company said it had a loss of 10 cents. Losses, adjusted for non-recurring costs and amortization costs, were 6 cents per share. The maker of ...
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the third quarter 2018.
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.
TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Stifel 2018 Healthcare Conference at The Lotte New York Palace Hotel in New York City.
Todd Pope became the CEO of TransEnterix Inc (NYSEMKT:TRXC) in 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
TransEnterix, Inc. announced today that it plans to release third quarter 2018 financial and operating results after the market closes on Thursday, November 8, 2018.
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, congratulates its President and Chief Executive Officer, Todd M. Pope, for being named to TIME Magazine's 50 Most Influential People in Health Care for 2018. In this inaugural list, Pope is highlighted for his role as one of those leaders whose work right now is transforming health care.
TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced demonstrations of its Senhance™ Surgical System at the American College of Surgeons (ACS) Clinical Congress 2018 at the Boston Convention & Visitors Center in Boston, MA, October 21 - 25. Surgeons, Hospital Administrators and related staff are invited to experience Senhance Surgery during the Company’s daily demonstrations located at the TransEnterix booth #577, from Monday, October 22 – Wednesday, October 24 from 10:30 a.m. – 11:30 a.m. ET.
Every investor in TransEnterix Inc (NYSEMKT:TRXC) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company received FDA 510(k) clearance for 3 millimeter diameter instruments, as well as additional 5 millimeter Senhance System instruments.